Lincoln Pharmaceuticals Share Price Target 2026 Analyst Forecast Bull and Bear Case
- June 24, 2026
- Posted by: Neeraj Pandey
- Category: News
The Lincoln Pharmaceuticals share price target 2026 is Rs 740, implying approximately 20 percent upside from the current market price of Rs 616.9 (NSE: LINCOLN). With Q4 FY26 results released in 2026 and Pharmaceutical Formulations and APIs tailwinds in focus, the Rs 740 price objective is supported by the FY27 earnings recovery thesis.
Lincoln Pharmaceuticals (NSE: LINCOLN) is a Pharmaceutical Formulations and APIs company trading at Rs 616.9 with a market capitalisation of Rs 1,544 crore. Analysts have set the Lincoln Pharmaceuticals share price target at Rs 740 for 2026, based on FY27 earnings projections and sector re-rating potential. This article covers the complete 2026 price forecast including sector tailwinds, key risks, and bull and bear scenarios.
Click Here – Get Free Investment Predictions
Lincoln Pharmaceuticals Share Price Target 2026: Key Takeaways
- Lincoln Pharmaceuticals share price target 2026: Rs 740 (20% upside from CMP Rs 616.9)
- Bull case: Rs 895 | Bear case: Rs 495
- Ticker: LINCOLN | Sector: Pharmaceutical Formulations and APIs | MCap: Rs 1,544 crore
- 52W range: Rs 427 to Rs 1,012 | PE: 20x
- Key catalyst: Q4 FY26 results and FY27 earnings confirmation in 2026
- Key risk: FY27 earnings miss or FII outflows from Indian equities
Lincoln Pharmaceuticals Company Overview
Lincoln Pharmaceuticals (NSE: LINCOLN) is an Ahmedabad-based manufacturer of branded pharmaceutical formulations across anti-infective, cardiac, and anti-diabetic segments for domestic and export markets, with growing API export to regulated international markets. At CMP Rs 616.9 against a 52 week range of Rs 427 to Rs 1,012, the stock trades at a meaningful discount to its 52 week high. Market capitalisation is Rs 1,544 crore with trailing PE of 20x. Compared to peers in pharma formulations like Alembic Pharmaceuticals and Ajanta Pharma, Lincoln Pharmaceuticals is positioned as a potential re-rating candidate toward the Rs 740 price objective on FY27 earnings delivery.
| Parameter | Value |
|---|---|
| NSE Ticker | LINCOLN |
| Sector | Pharmaceutical Formulations and APIs |
| CMP (2026) | Rs 616.9 |
| 52 Week High | Rs 1,012 |
| 52 Week Low | Rs 427 |
| Market Cap | Rs 1,544 crore |
| Trailing PE | 20x |
| 12-Month Analyst Target | Rs 740 |
| Bull Case Target | Rs 895 |
| Bear Case Target | Rs 495 |
Why Is the Lincoln Pharmaceuticals Share Price Target Set at Rs 740 for 2026
FY27 Earnings Recovery and Revenue Acceleration
The Lincoln Pharmaceuticals share price target of Rs 740 rests on analyst projections of 15 to 20 percent PAT growth in FY27. Q4 FY26 results released in 2026 confirming the earnings trajectory are the most direct catalyst for re-rating. The Rs 740 price objective represents the base case with FY27 execution as the key variable.
Structural Sector Tailwinds in Pharmaceutical Formulations and APIs
The Pharmaceutical Formulations and APIs sector is expanding on the back of India’s domestic demand growth, PLI scheme support, and rising corporate investment. Lincoln Pharmaceuticals’s position among peers in pharma formulations like Alembic Pharmaceuticals and Ajanta Pharma creates a structural growth runway. Sustained outperformance is one of the key conditions for the Rs 895 bull case to materialise.
RBI Rate Cut Cycle and Lower Cost of Capital
India’s RBI rate cut cycle in 2026 is reducing borrowing costs and stimulating end market demand. Lower interest costs improve Lincoln Pharmaceuticals’s EPS trajectory, narrowing the gap between current earnings and the FY27 estimates that underpin the Rs 740 analyst consensus.
Union Budget 2026-27 Capex Push and Policy Support
Budget 2026-27’s Rs 11.21 lakh crore infrastructure capex and PLI scheme continuity create a favourable backdrop for Lincoln Pharmaceuticals’s Pharmaceutical Formulations and APIs operations, improving the probability of achieving the Rs 740 price objective through FY27 earnings delivery.
FII Flow Normalisation After the 2026 Tariff Shock
As global macro conditions normalise through 2026, FII flows into quality Indian equities are gradually recovering. At 20x PE, Lincoln Pharmaceuticals is positioned as a beneficiary of institutional reallocation, providing a tailwind toward the Rs 895 bull case over the medium term.
Lincoln Pharmaceuticals Share Price Targets: Short Term, 12 Month, and Long Term
Short Term Lincoln Pharmaceuticals Share Price Target
Near-term support for Lincoln Pharmaceuticals is anchored close to the 52 week low of Rs 427. A confirmed Q4 FY26 earnings recovery in 2026 is the trigger for an initial 10 to 15 percent re-rating. Investors can use the 52 week low as an entry reference while awaiting FY27 earnings confirmation.
12-Month Lincoln Pharmaceuticals Share Price Target 2026
The 12-month Lincoln Pharmaceuticals share price target 2026 is Rs 740, implying approximately 20 percent upside from CMP Rs 616.9. This base case assumes in-line FY27 earnings delivery and partial normalisation of FII flows. Track live on NSE ticker LINCOLN.
Long Term Lincoln Pharmaceuticals Share Price Target: FY27 to FY28
The long term Lincoln Pharmaceuticals share price target for FY27 to FY28 is Rs 895 in the bull case, requiring full earnings delivery, re-rating among peers in pharma formulations like Alembic Pharmaceuticals and Ajanta Pharma, and sustained institutional buying over a 2 to 3 year horizon.
Bull Case and Bear Case Scenarios for Lincoln Pharmaceuticals in 2026
Bull Case Lincoln Pharmaceuticals Share Price Target: Rs 895
The bull case Lincoln Pharmaceuticals share price target of Rs 895 materialises when FY27 earnings beat analyst estimates, Pharmaceutical Formulations and APIs tailwinds accelerate, and FII flows return strongly to Indian equities. From CMP Rs 616.9, this represents approximately 45 percent potential upside.
Bear Case Lincoln Pharmaceuticals Share Price Target: Rs 495
The bear case Lincoln Pharmaceuticals share price target of Rs 495 materialises if FY27 earnings disappoint or FII outflows depress the broader market, risking a test of support near the 52 week low of Rs 427.
| Scenario | Target | Key Conditions |
|---|---|---|
| Bull Case | Rs 895 | FY27 beat, sector re-rating, FII inflows |
| Base Case (Analyst Target) | Rs 740 | In-line FY27 delivery, partial FII recovery |
| Bear Case | Rs 495 | FY27 miss, guidance cut, FII outflows persist |
Key Risks That Could Derail the Lincoln Pharmaceuticals 2026 Price Objective
Global Macro and US Tariff Headwinds
Prolonged tariff tensions and global demand slowdown remain prominent macro risks to the Lincoln Pharmaceuticals share price target of Rs 740, with FII outflows being the direct transmission mechanism to Indian equity valuations.
FY27 Earnings Miss and Guidance Risk
An FY27 earnings miss or downward guidance revision would compress valuation multiples. This is the most direct company-specific risk to the Rs 740 analyst price objective. Investors must monitor quarterly results and management commentary closely.
Competitive Intensity Among Pharmaceutical Formulations and APIs Peers
Intensifying competition from peers in pharma formulations like Alembic Pharmaceuticals and Ajanta Pharma could compress Lincoln Pharmaceuticals’s market share and pricing power. This structural risk must be weighed when assessing the defensibility of the earnings trajectory underpinning the Rs 740 analyst target for 2026.
Liquidity Risk and FII Selling Pressure
Sustained FII outflows from Indian equities can delay the re-rating process regardless of company-level improvement. Investors should maintain position sizing discipline and stop losses to protect capital.
How to Invest in Lincoln Pharmaceuticals
Check the Univest Screener for live data
Before considering any investment based on the Lincoln Pharmaceuticals share price target of Rs 740, review Q4 FY26 results and FY27 guidance released in 2026. Focus on revenue growth, margin trends, and management commentary on Pharmaceutical Formulations and APIs sector demand.
Open a Demat account with a SEBI registered stockbroker to trade Lincoln Pharmaceuticals (NSE: LINCOLN) with regulatory protection. Study the competitive landscape among peers in pharma formulations like Alembic Pharmaceuticals and Ajanta Pharma before executing any position.
Plan your entry using the 52 week low of Rs 427 as a key support reference. A confirmed FY27 earnings uptick validates the entry case for the Rs 740 price objective. Always set a stop loss below the 52 week low.
Restrict any single stock to 3 to 5 percent of your total equity portfolio. Always consult a SEBI registered financial advisor before investing. SEBI Registration No. INH000013776.
Download the Univest iOS App or the Univest Android App to track Lincoln Pharmaceuticals’s live share price and receive daily stock recommendations.
Disclaimer Note: The securities quoted, if any, are for illustration only and are not recommendatory. This content is for educational purposes only and does not constitute investment advice. Investments in securities are subject to market risk. Read all related documents carefully before investing. SEBI Registration No. INH000013776.
FAQs on Lincoln Pharmaceuticals Share Price Target 2026
What is the Lincoln Pharmaceuticals share price target for 2026?
Ans. The Lincoln Pharmaceuticals share price target 2026 is Rs 740, implying approximately 20 percent upside from CMP Rs 616.9. Bull case is Rs 895, bear case is Rs 495.
What was the Lincoln Pharmaceuticals share price target for 2025?
Ans. The 2025 price objective for Lincoln Pharmaceuticals was based on FY26 earnings projections. The current 2026 analyst consensus is Rs 740, reflecting FY27 growth potential from CMP Rs 616.9.
Is Lincoln Pharmaceuticals a good investment at Rs 616.9?
Ans. At Rs 616.9, Lincoln Pharmaceuticals offers potential upside toward Rs 740 if FY27 earnings recover. Whether this represents a good entry depends on individual risk tolerance. Consult a SEBI registered financial advisor before investing.
What are the key risks to the Lincoln Pharmaceuticals share price target 2026?
Ans. Key risks to the Lincoln Pharmaceuticals share price target of Rs 740 include FY27 earnings miss, global tariff headwinds, FII outflows, and competitive pressure in Pharmaceutical Formulations and APIs. Monitoring quarterly results is essential.
What is the 52 week high and low of Lincoln Pharmaceuticals?
Ans. The 52 week high of Lincoln Pharmaceuticals is Rs 1,012 and the 52 week low is Rs 427. At CMP Rs 616.9, the stock offers potential upside toward the Rs 740 price objective.
What are the main growth catalysts for Lincoln Pharmaceuticals in 2026?
Ans. Key catalysts include FY27 PAT recovery, Pharmaceutical Formulations and APIs tailwinds, RBI rate cuts in 2026, Budget 2026-27 policy support, and normalisation of FII flows into Indian equities.
How does Lincoln Pharmaceuticals compare to its peers?
Ans. Lincoln Pharmaceuticals operates in Pharmaceutical Formulations and APIs alongside peers in pharma formulations like Alembic Pharmaceuticals and Ajanta Pharma. At CMP Rs 616.9 with MCap Rs 1,544 crore, it is a potential re-rating candidate toward the Lincoln Pharmaceuticals share price target of Rs 740 on FY27 delivery.
What is the Lincoln Pharmaceuticals share price target for 2027?
Ans. The long-term Lincoln Pharmaceuticals share price target for FY27 to FY28 is Rs 895 in the bull case, assuming earnings growth, sector re-rating, and FII inflows. Consult a SEBI registered financial advisor for personalised guidance.
